In November 2020, the U.S. Food and Drug Administration (FDA) approved Keytruda (pembrolizumab) in combination with chemotherapy for unresectable locally advanced or metastatic TN, PD-L1-positive breast cancers based on the results of the KEYNOTE-355 clinical trial [43]. Here, CD274 is linked to breast cancer.